Chiesi Farmaceutici has been granted a patent for a process to prepare compounds with PDE4 inhibitory activity, suitable for inhalation in pharmaceutical compositions for respiratory disease treatment. The patent also covers solvates and crystal forms of the compound. GlobalData’s report on Chiesi Farmaceutici gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Chiesi Farmaceutici SpA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Chiesi Farmaceutici, Inhalation devices was a key innovation area identified from patents. Chiesi Farmaceutici's grant share as of May 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical formulation with pde4 inhibitory activity for inhalation

Source: United States Patent and Trademark Office (USPTO). Credit: Chiesi Farmaceutici SpA

A recently granted patent (Publication Number: US11981639B2) discloses a pharmaceutical formulation that includes a crystal form of a compound of formula (I). The formulation is designed for inhalation or intranasal administration and can also be in the form of a capsule or dry powder suitable for inhalation. This innovative formulation aims to treat inflammatory or obstructive respiratory diseases effectively.

Moreover, the patent also covers a process for preparing the crystal form of the compound of formula (I), ensuring that the total amount of impurities in the crystal is minimal, ranging from less than 5% w/w to as low as 0.5% w/w. The process involves specific steps such as heating a suspension of the compound in ethyl acetate/heptane or isopropyl acetate under controlled conditions. The resulting crystal form, with a high percentage of crystallinity exceeding 90% w/w, is crucial for the efficacy of the pharmaceutical formulation. This crystal form can be utilized in the treatment of inflammatory or obstructive respiratory diseases like asthma or chronic obstructive pulmonary disease, offering a promising therapeutic approach for patients in need.

To know more about GlobalData’s detailed insights on Chiesi Farmaceutici, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies